CanSino Biologics Inc
06185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,105
Stocks News & Analysis
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
A round up of notable stories and reactions as ASX earnings season continues.
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,234.30 | 55.70 | -0.60% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,339.14 | 234.53 | 0.93% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
| NZX 50 Index | 13,042.76 | 151.31 | -1.15% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
| SSE Composite Index | 3,825.76 | 54.66 | 1.45% |